Chargement en cours...
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung cancer (NS...
Enregistré dans:
| Publié dans: | Oncol Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360008/ https://ncbi.nlm.nih.gov/pubmed/32700194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-019-0092-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|